As for risk of relapse, several subsequent editions of the St.Gallen guidelines [4,6,16], widely accepted as a reasonable approach to the treatment of early breast cancer, rule out that patients with ER/PgR-negative can be considered at minimal risk. This evidence concerns the gene ESR1 and breast cancer.